Anteris Technologies (ASX:AVR) - Medical Advisory Board Member, Dr Paul Sorajja
Medical Advisory Board Member, Dr Paul Sorajja
Dr Paul Sorajja Source: LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Anteris Technologies (AVR) implants five TAVR patients in a first-in-human study to treat severe aortic stenosis in Georgia
  • The study aimed to assess the DurAVR THV system for treating the disease, with the transcatheter aortic valve replacement (TAVR) procedures pronounced successful and without complications by Anteris
  • The company says the first five patients go a long way in proving the unique benefits of the DurAVR valve, validating its prior preclinical work
  • An additional five patients are planned for treatment in the first quarter of 2022 to conclude the study
  • Anteris Technologies is up 13.7 per cent, trading at $10.10 at 2:50 pm AEDT

Anteris Technologies (AVR) has implanted five TAVR patients in a first-in-human study to treat severe aortic stenosis in Georgia.

The study aimed to assess the DurAVR THV system for treating the disease, which sees a patient’s heart’s aortic valve narrow, reducing blood flow from the heart to the main artery of the body.  

The trial looked to determine the correct positioning of the DurARV valve in the proper anatomical location, as well as haemodynamic performance, assessed after both 30 days and one year. DurAVR is a 3D single-piece aortic valve for the treatment of aortic stenosis.

The transcatheter aortic valve replacement (TAVR) procedures were all pronounced successful by Anteris, and without complications.

The company said the first five patients go a long way in proving the unique benefits of the DurAVR valve and validating the prior preclinical work, with results to date looking better than anticipated.

“In this early experience, DurAVR showed superior haemodynamic with some of the largest effective orifice areas I have seen in any TAVR platform,” Dr Paul Sorajja, Medical Advisory board member of Anteris said.

“Remarkably, this was observed with rapid deployment techniques and standard implant depths and in small aortic annular areas. Importantly, there were no adverse events.

“This technology allows us to provide superior haemodynamic with a balloon expandable platform.”

An additional five patients are planned for treatment in the first quarter of 2022 to conclude the study.

Anteris Technologies was up 13.7 per cent, trading at $10.10 at 2:50 pm AEDT.

AVR by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…